Cannabinoids are gaining traction in the therapeutic space, offering potential benefits beyond their current approved uses in epilepsy, multiple sclerosis, and chemotherapy-induced nausea. Emerging research highlights their promise in pain management and treating central nervous system disorders related to stress and anxiety. This whitepaper explores the growing body of science behind cannabinoid-based medicines, guiding stakeholders through the complexities of drug development in this rapidly evolving field—from selecting the right active ingredients to enhancing patient compliance. Download to learn more about navigating cannabinoid innovation and maximizing therapeutic potential.
Discover how dsm-firmenich is tackling the challenge of bitter medicine with a receptor-based technology designed to elevate drug palatability and improve patient adherence.
Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.
Discover the top 5 trends transforming pharma regulations in Asia-Pacific and how drug developers can navigate this evolving landscape with dsm-firmenich.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.